Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Andrew P. Groves
PRIMARY OUTCOME Phase I To determine the safety and maximum tolerated dose (MTD) of intrathecal (IT) azacitidine in combination with IT nivolumab in patients with recurrent high-grade glioma Expansion Cohort To estimate the overall response rate (ORR) SECONDARY OUTCOMES To estimate: 1. Duration of response (DOR) 2. Progression-free survival (PFS) 3. Overall survival (OS) EXPLORATORY OUTCOMES Changes in immune profiling (flow cytometry, cytokine/chemokine analysis) and circulating tumor DNA (ctDNA) biomarkers (quantification, DNA methylation)
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted